<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683124</url>
  </required_header>
  <id_info>
    <org_study_id>FARM7KP2PX</org_study_id>
    <secondary_id>EudraCT 2008−001462−81</secondary_id>
    <nct_id>NCT00683124</nct_id>
  </id_info>
  <brief_title>Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients</brief_title>
  <acronym>MaNeLo</acronym>
  <official_title>Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major clinical problems in patients with Marfan Syndrome (MFS) are aortic root dilation
      (ARD), dissection and rupture. Although the available treatments (beta-blockers, BBs) improve
      the evolution of the disease, they do not protect MFS patients from progression of ARD and
      dissection. A key molecule that negatively influences cell growth, differentiation, survival
      and death in MFS is TGFb which is antagonised by existing drugs employed in the clinical
      practice, the Angiotensin II receptor blockers (ARB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marfan Syndrome is a rare disease (1:5000)(MIM#154700) caused by mutations of the Fibrillin 1
      (FBN1) gene. The major clinical problem is aortic aneurysm with risk of dissection when root
      diameter is 5 cm.

      The investigators designed a clinical trial in which a new generation Beta-Blocker Nebivolol
      with expected effects on shear stress, heart rate and potential anti-stiffness benefits is
      compared to Losartan, and Angiotensin receptor blocker anti TGF-beta effects, and to the
      association of both molecules in patients with Marfan Syndrome. Nebivolol is a patented drug
      that differs chemically, pharmacologically and therapeutically from all other BBs. Nebivolol
      shows the highest selectivity for ß1 receptors among the currently available BBs, influences
      the arterial stiffness through an agonistic effect on ß2-receptors and preserves the arterial
      compliance. We expect a significantly lower progression of the Aortic Root Dilation in the
      arm of Nebivolol plus Losartan vs. single drug (primary end-point).The investigators further
      expect: decrease of arterial stiffness higher in the arm treated with both drugs than in
      solely Nebivolol or Losartan; a decrease of serum levels of active TGFb in both Losartan
      arms, a drug &amp; age-dependant variation of the expression of the mutated FBN1 gene. As for
      other end-points, the potential results are the improvement of valve function, hard events &amp;
      delay of surgical timing for the aortic root. The enrolment period will last 12 months, while
      the overall follow-up period will be of 4 years. An interim analysis for the primary outcome
      is programmed at month 24.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BSA and age-adjusted aortic root diameter (sinuses of Valsalva)</measure>
    <time_frame>every 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of the two drugs by age and dosages</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation of the serum levels of total and active TGFb</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative assessment of the expression of the mutated gene (FBN1, both 5' and 3')</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic bases of drug responsiveness (Losartan: CYP2C9 gene) (Nebivolol: CYP2D6 gene)</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve regurgitation severity</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic diameter</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometric lung volumes and flows</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL evaluation basing on SF-36 questionnaire</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness (carotids)</measure>
    <time_frame>every 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan+Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan and nebivolol</intervention_name>
    <description>Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.
Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations</description>
    <arm_group_label>Losartan+Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MFS: Ghent criteria and genetically proven defect of the FBN1 gene

          -  Age: 12 months to 55 years

          -  BSA-adjusted aortic z score = or &gt;2 measured at the level of the sinuses of Valsalva
             at baseline according to Roman's method, or absolute aortic root diameter &gt;38mm for
             females and &gt;40 mm for males

        Exclusion Criteria:

          -  Prior aortic surgery and/or dissection

          -  Aortic root diameter at the level of the sinuses of Valsalva 5 cm

          -  Planned aortic surgery within 6 months of enrollment for a rate of ARD progression&gt;5
             mm/year even in pts with ARD less than 5 cm

          -  Clinical or molecular diagnosis of non-MFS connective tissue diseases sharing some
             features with MFS (Shprintzen-Goldberg syndrome or Loeys-Dietz syndromes)

          -  Un-renounceable therapeutic (systemic hypertension, arrhythmia, ventricular
             dysfunction, valve regurgitation) use of drugs such as ACE inhibitors, BBs, or
             calcium-channel blockers

          -  Known side-effects while taking an ARB or a BB

          -  Intolerance to ARB that resulted in termination of therapy

          -  Intolerance to BB that resulted in termination of therapy

          -  Renal dysfunction (creatinine level more than upper limit of age-related normal
             values)

          -  Diabetes mellitus

          -  Pregnancy or planned pregnancy within 48 months of enrollment

          -  Technical limitations for the imaging studies including poor acoustic windows with
             limits the accurate measurement of aortic root

          -  Asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloisa Arbustini, MD,FESC,FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Foundation San Matteo Hospital, Pavia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Tavazzi, MD,FESC,FACC</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Foundation San Matteo Hospital, Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eloisa Arbustini, MD,FESC,FACC</last_name>
    <phone>+390382501206</phone>
    <email>e.arbustini@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabiana I Gambarin, MD</last_name>
    <phone>+390382501206</phone>
    <email>f_gambarin@yahoo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Foundation San Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloisa Arbustini, MD,FESC,FACC</last_name>
      <phone>+390382501206</phone>
      <email>e.arbustini@smatteo.pv.it</email>
    </contact>
    <contact_backup>
      <last_name>Fabiana I Gambarin, MD</last_name>
      <phone>+390382501206</phone>
      <email>f.gambarin@smatteo.pv.it</email>
    </contact_backup>
    <investigator>
      <last_name>Eloisa Arbustini, MD,FESC,FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabiana I Gambarin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Favalli, Engineer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Serio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Regazzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Klersy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997 May;51(5):1376-82. Review.</citation>
    <PMID>9150447</PMID>
  </reference>
  <reference>
    <citation>Hao J, Wang B, Jones SC, Jassal DS, Dixon IM. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H3020-30.</citation>
    <PMID>11087260</PMID>
  </reference>
  <reference>
    <citation>Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998 Jan;31(1 Pt 2):181-8. Review.</citation>
    <PMID>9453300</PMID>
  </reference>
  <reference>
    <citation>Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001 Feb 13;103(6):789-91.</citation>
    <PMID>11171784</PMID>
  </reference>
  <reference>
    <citation>Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol. 1988 Dec;34(6):843-51.</citation>
    <PMID>2462161</PMID>
  </reference>
  <reference>
    <citation>Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl. 2004 Oct;1:2-16. Review.</citation>
    <PMID>15587107</PMID>
  </reference>
  <reference>
    <citation>McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkinson IB, Cockcroft JR. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004 Sep;44(3):305-10. Epub 2004 Jul 19.</citation>
    <PMID>15262912</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.</citation>
    <PMID>1593914</PMID>
  </reference>
  <reference>
    <citation>Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005 Aug;18(8):1060-6.</citation>
    <PMID>16296572</PMID>
  </reference>
  <reference>
    <citation>Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998 Dec;38(6):419-31. Review.</citation>
    <PMID>9990650</PMID>
  </reference>
  <reference>
    <citation>Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol. 1989 Sep 1;64(8):507-12.</citation>
    <PMID>2773795</PMID>
  </reference>
  <results_reference>
    <citation>Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21.</citation>
    <PMID>16601194</PMID>
  </results_reference>
  <results_reference>
    <citation>Selamet Tierney ES, Feingold B, Printz BF, Park SC, Graham D, Kleinman CS, Mahnke CB, Timchak DM, Neches WH, Gersony WM. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr. 2007 Jan;150(1):77-82.</citation>
    <PMID>17188619</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007 Oct 3;298(13):1539-47. Retraction in: JAMA. 2015 Dec 22-29;314(24):2692-3.</citation>
    <PMID>17911499</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Doctor Eloisa Arbustini, MD, FESC, FACC</name_title>
    <organization>IRCCS Foundation San Matteo Hospital</organization>
  </responsible_party>
  <keyword>Marfan Syndrome</keyword>
  <keyword>Losartan</keyword>
  <keyword>Nebivolol</keyword>
  <keyword>Transforming Growth Factor Beta</keyword>
  <keyword>Aortic Root Dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

